Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
April 13 2009 - 8:30AM
Business Wire
Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company
focused on the discovery and development of small-molecule
therapeutics for the treatment of gout, human immunodeficiency
virus (HIV), cancer and inflammatory diseases, today announced
event participants and webcast information for its Investor and
Analyst Event on Monday, April 20, 2009 from 5:00 p.m. to 7:00 p.m.
Eastern Daylight Time in New York City.
Ardea will present results from its recently completed Phase 1
studies of RDEA594, its lead product candidate for the treatment of
hyperuricemia and gout, and Phase 2a study of RDEA806, RDEA594�s
prodrug, in patients with gout. Plans for the Phase 2 development
program with RDEA594, scheduled to start in the second quarter of
2009, will also be presented. Panel discussion participants are
expected to include Ardea management and key opinion leaders in the
field of gout and hyperuricemia, including:
Mark C. Genovese, MDAssociate Professor of Medicine and Co-Chief
of the Division of Immunologyand RheumatologyStanford University
Medical CenterPalo Alto, CA(via video conference)
and
Fernando Perez-Ruiz, MD, PhDAssistant Head of the Rheumatology
DivisionHospital de CrucesVizcaya, Spain
To access the webcast, please log onto Ardea�s website at
www.ardeabio.com and click on the Investors Center section
approximately 10 minutes prior to the start of the webcast to allow
for any software downloads that may be necessary. An archived
recording of the event will be available on Ardea�s website for one
month.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego,
California, is a biotechnology company focused on the discovery and
development of small-molecule therapeutics for the treatment of
gout, human immunodeficiency virus (HIV), cancer and inflammatory
diseases. We have five product candidates in clinical trials and
others in preclinical development and discovery. Our most advanced
product candidate is RDEA806, a non-nucleoside reverse
transcriptase inhibitor (NNRTI), which has successfully completed a
Phase 2a study for the treatment of patients with HIV. We have
evaluated our second-generation NNRTI for the treatment of HIV,
RDEA427, in a human micro-dose pharmacokinetic study and have
selected it for clinical development based on a plasma half-life of
greater than 40 hours. RDEA594, our lead product candidate for the
treatment of hyperuricemia and gout, is being evaluated in Phase 1
clinical trials. We are evaluating our lead MEK inhibitor, RDEA119,
in a Phase 1/2 study in combination with sorafenib (Nexavar�, Onyx
Pharmaceuticals, Bayer HealthCare) and as a single agent in a Phase
1 study, both in advanced cancer patients, and have completed a
Phase 1 study in normal healthy volunteers as a precursor to trials
in patients with inflammatory diseases. Lastly, we have evaluated
our second-generation MEK inhibitor for the treatment of cancer and
inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development.
Statements contained in this press
release regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding our plans and goals, the expected properties
and benefits of RDEA806, RDEA594, RDEA427, RDEA119, RDEA436 and our
other compounds and the timing and results of our preclinical,
clinical and other studies. Risks that contribute to the uncertain
nature of the forward-looking statements include risks related to
the outcome of preclinical and clinical studies, risks related to
regulatory approvals, delays in commencement of preclinical and
clinical studies, costs associated with our drug discovery and
development programs, and risks related to the outcome of our
business development activities. These and other risks and
uncertainties are described more fully in our most recently filed
SEC documents, including our Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, under the headings "Risk Factors."
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jul 2023 to Jul 2024